[KR-바이오] 06/18 Korea Market Insights

Samsung Biologics is currently facing significant internal headwinds as labor-management relations deteriorate, marked by a month-long compliance strike. While the company has achieved impressive financial growth and competitive compensation levels, the shift toward a “hard-line” stance between the union and management poses a risk to operational stability.

The ongoing legal proceedings regarding the recognition of “24-hour continuous processes” further complicate the labor dispute, as these regulations directly impact workforce management and production efficiency. Investors should monitor whether the company can adopt a “package deal” strategy—similar to Samsung Electronics’ historical approach—to resolve these industrial relations issues before they escalate into broader production disruptions or reputational damage.

Celltrion’s recent decision to initiate a share buyback program worth 270 billion KRW serves as a strong signal of management’s confidence in the company’s intrinsic value and commitment to shareholder return policies. This move is expected to stabilize the stock price and mitigate volatility amid broader market uncertainties.

Simultaneously, the company’s strategic pivot toward a ‘quadruple-action’ obesity treatment demonstrates a proactive R&D approach to surpass current market leaders. By targeting a next-generation therapeutic profile, Celltrion is positioning itself to capture significant market share in the high-growth obesity drug sector, effectively diversifying its pipeline beyond traditional biosimilars.

Yuhan Corporation is currently at a critical inflection point as it approaches its 100th anniversary, transitioning from a domestic leader to a global pharmaceutical player. The recent interest from BlackRock, the world’s largest asset manager, serves as a strong institutional endorsement of the company’s long-term growth potential.

The primary catalyst remains the commercial success of Leclaza (Lazertinib), which has validated the company’s R&D capabilities on the global stage. By moving beyond its traditional domestic footprint, Yuhan is strategically positioning itself to enter the Global Top 50 pharmaceutical rankings. While the company continues to emphasize its corporate social responsibility and legacy, the market focus is firmly fixed on its ability to monetize its proprietary pipeline and sustain high-margin growth through international partnerships. We view the institutional accumulation as a signal of confidence in Yuhan’s structural transformation.

Alteogen is currently entering a pivotal phase of commercialization and platform expansion. The recent domestic approval of the Keytruda SC (subcutaneous) formulation serves as a critical proof-of-concept for the company’s proprietary ALT-B4 (hyaluronidase) platform. With the transition from clinical development to commercial revenue, the company is well-positioned to capture significant milestone payments and recurring royalties. Furthermore, the expansion into ADC (Antibody-Drug Conjugate) SC formulations demonstrates a clear strategy to diversify its pipeline and maintain a competitive edge in the next-generation drug delivery market. As patent-related uncertainties subside, the company’s ability to secure additional global partnerships will be the primary driver for long-term valuation re-rating.

HLB is currently at a critical juncture as it awaits the final FDA approval decision for its flagship drug, Rivoceranib. While the company is actively pursuing a long-term growth strategy by expanding its pipeline into CAR-T and FGFR2 therapies, market sentiment remains volatile due to concerns over capital structure adjustments, such as recent capital increases, and regulatory uncertainties surrounding its intellectual property portfolio. Investors are advised to exercise caution, as the stock is highly sensitive to both the binary outcome of the FDA review and the company’s internal corporate restructuring efforts.